Back to search results

Phase 2 Study of Budoprutug for Primary Membranous Nephropathy

This study is testing a drug called budoprutug for people with primary membranous nephropathy (PMN), a kidney disease. Budoprutug is a monoclonal antibody that works by targeting specific cells in the body. The main goal is to see how safe budoprutug is and if people can tolerate it. You might be able to join if you are between 18 and 75 years old, have a confirmed diagnosis of PMN with positive anti-PLA2R antibodies, and meet other health requirements, including specific kidney function levels. The study plans to enroll about 45 participants. We don't have information on the current recruitment status.

Study design
This is an open-label, Phase 2 study, meaning you and your doctors will know which treatment you are receiving. It will involve about 45 participants.
What's involved
Participants will receive budoprutug intravenously (through a vein) on Day 1, Day 15, Day 169, and Day 183. You will be followed for up to 48 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through Week 48, with extended follow-up for B-cell recovery as needed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07096843

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Climb Bio, Inc.
~45 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:budoprutug

At a glance

Recruiting sites
32 of 43 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Measured over Up to Week 48

Conditions

Primary Membranous Nephropathy

Explore related trials

Primary Membranous Nephropathyanti-PLA2RCD19 Gene

Where it's being run

43 sites across 22 states
Brazil6
Argentina5
Taiwan5
Ukraine5
Georgia4
Shandong2
Colorado1
Florida1

Who to contact

Climb Bio Study Director
[email protected]
+1 866 857 2596
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Confirmed diagnosis of PMN with positive anti-PLA2R antibodies
CD19+ B cell count ≥40 cells/μL
UPCR ≥2.0 g/g
eGFR ≥35 mL/min/1.73 m²
Stable RAAS inhibitor therapy
Blood pressure \<150/90 mmHg at baseline
Adequate hematologic, hepatic, and renal function
Willing to use effective contraception (both sexes)

Exclusion

Secondary Membranous Nephropathy
Rapidly progressive glomerulonephritis or other glomerulopathies
Prior B cell-depleting therapy within 24 weeks
Recent use of immunosuppressants
Active or high-risk infections
History of malignancy
Pregnancy or breastfeeding
Recent major surgery or hospitalization

What this trial measures

  • Incidence of Treatment-Emergent Adverse Events (TEAEs)Up to Week 48

    Number of participants experiencing TEAEs, graded per NCI CTCAE v5.0.